Surgery Partners, Inc. (SGRY) Q4 FY25 Earnings Call

2026 guidance resets EBITDA growth to at least 0.7% while embedding identified market, reimbursement, tariff, and payer-mix pressures. [23][25][26]

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-04
Length62 minutes
EPS$0.10
Revenue$821.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

All SGRY earnings ยท Back to SGRY overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.